SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cadus Pharmaceutical Corp. (KDUS)
KDUS 1.6000.0%Jul 2 5:00 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (201)6/19/2000 10:59:00 AM
From: scaram(o)uche  Read Replies (1) of 1833
 
Outstanding article (thanks for pointer, Peter) in today's BioCentury by Karen Bernstein.

Only omission is.... no mention of recent PTO office action in favor of KDUS. Isn't that a critical question to ask.... why would OSIP license from Merck if the office action has weight? The obvious answer, if Pfizer-OSIP are showing all their cards, is that it doesn't have weight. The other hard question to ask.... what role did the Pfizer-Merck (Sibia) lawsuit play in this, if any??

With respect to the wisdom behind an investment in KDUS, one needs to again look at the complexity introduced by the Cyanimid patents, but note also the comment...... "that was the original cause of the dispute, so there's a distinct business reason to clear it up as well."

At a market cap of 10 million, one needs to look at "While OSI could have used the GPCR-yeast system without the TBA patents, the other methods are more cumbersome."

and.......

"We knew that Cadus' core technology was very powerful".

There is encouraging commentary about what the technologies mean for the future of OSIP, and that's only upside for KDUS.

Sincerely hoping that the sellers continue to sell,

Rick
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext